Alternatively, our findings could indicate that adding highly effective anti-inflammatory agents, such as the cyclooxygenase-2 inhibitor celecoxib, to the treatment algorithm of CARWL-2 patients may improve their results, given Komaki and colleagues' impressive results in unresectable locally advanced NSCLC patients [28]. This evidence concerns the gene PTGS2 and non-small cell lung carcinoma.